Manufacturer Solutions

Creating Sustainability & Longevity for Biosimilars

 

At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.
Biosimilars and the US market

For manufacturers

Distribution & commercialization services

Our experts can help you devise channel strategies and tailored solutions for access and uptake. And, we have market-leading reach into the sites of care where patients are being treated with biosimilars.
Benefits of Biosimilars

For providers

Education, solutions & support

Our market-leading GPOs connect physicians and manufacturers for unrivaled purchasing power and education while our provider solutions offer tailored services for all sites of care. Plus, field reimbursement support helps practices navigate payment for these new products.
Patient access to Biosimilars

For patients

Impacting access, affordability & adherence

Our patient assistance program (PAP) models and adherence services are tailored to your product and patient needs and integrate seamlessly with our reimbursement and co-pay services.

Our relationships span:

Nearly

100%

of U.S. hospitals and health systems

Oncology

60%

of U.S. community oncology market

Nephrology

90%

of U.S. renal market

Rheumatology

2,100

provider sites

Ophthalmology

4,200

provider sites

  A guide for understanding the growing market

Biosimilar Pipeline Report

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 
Manufacturer of biosimilars

We advance access with integrated commercialization services for all biosimilars

Field Reimbursement for Biosimilars

Field reimbursement support
Powered by Xcenda
Access to Biosimilars via GPO

GPO access & provider education
Powered by ION Solutions
Patient support for FDA approved Biosimilars

HUB & patient services
Powered by Lash Group
Market access for Biosimilars

Market access consulting
Powered by Xcenda

FDA guidance on approved Biosimilars on the market

Resources & education

FDA guidance on approved Biosimilars on the market

Read the FDA's guidance on biosimilars and get answers to patients' frequently asked questions.

FDA guidance on approved Biosimilars on the market

"The right conditions exist in the U.S. for biosimilar commercialization success. Competition has proven to bring prices down – look at the generics market over the last 30 years – but now we need to create a supportive system."

Steve Collis, Chairman, President and CEO, AmerisourceBergen 

Biosimilars vs generics
Sean McGowan Senior Director, Biosimilars, AmerisourceBergen

Connect with an expert

Sean McGowan Senior Director, Biosimilars, AmerisourceBergen
Find out more about how AmerisourceBergen can support your product or practice as the biosimilars market in the U.S. expands.

Sean McGowan, Senior Director Biosimilars
Sean McGowan Senior Director, Biosimilars, AmerisourceBergen

Related Insights

Podcast: Insulin biosimilars part 1

In part one of a two-part series on insulin biosimilars, we’ll talk about what these new drugs could mean for the category.. 

The changing Biosimilars landscape

COVID-19 changed the way physician practices and health systems interacted with patients. The pandemic has presented opportunities for greater engagement with customers who are building a strategy around adoption and cost savings.

It has been a successful year, and 2021 looks just as promising. Sean McGowan anticipates new manufacturers and a second wave of products into existing biosimilar markets.

Physician Q&A: How to Boost Confidence in Biosimilars

Biosimilars have the potential to reduce healthcare costs in the United States — but only if the market grows. Dr. Kashyap Patel, Medical Director at Carolina Blood and Cancer Care, provides perspective on how manufacturers can help deliver on the promise of cost savings by improving physician confidence in biosimilars.

In the News

Media Mention

Allen Lising of Xcenda sits down with The Center for Biosimilars

AMJC | The Center for Biosimilars
May 5, 2021

Media Mention

Report: Biosimilars have significantly lowered prices of all biologics

Biosimilars Forum
April 15, 2021

Media Mention

Five Years On, Biosimilars Need Support From All Health Care Players

STAT News, Sean McGowan
March 6, 2020